Context: Measurement of plasma cortisol by immunoassay after ACTH stimulation is used to assess the hypothalamic-pituitary-adrenal (HPA) axis. Liquid chromatography-tandem mass spectrometry (LCMS) has greater analytical specificity than immunoassay and equilibrium dialysis allows measurement of free plasma cortisol.
ic-pituitary-adrenal (HPA) axis in patients at risk of secondary adrenal dysfunction can be a diagnostic challenge.
Assessment for secondary adrenal dysfunction relies on interpretation of basal cortisol concentration and change in cortisol concentration in response to physiological or pharmacological stimuli. The insulin hypoglycemia test (IHT) is considered the gold-standard test of the HPA axis in patients with pituitary disease (2, 3) . However, the IHT is resource intensive, is unpleasant for patients, and carries a small risk of seizure or loss of consciousness. This has contributed to the common use of ACTH tests to assess HPA function in patients with pituitary disease (4, 5) . The peak cortisol after ACTH stimulation provides important prognostic information regarding HPA function in pituitary patients (6) . However, it is primarily a test of adrenal (rather than pituitary) function. Furthermore, the sensitivity of ACTH stimulation testing to define secondary adrenal failure is only 60% when compared with the IHT or metyrapone tests (7) .
Current assessment of HPA function is based on the measurement of total cortisol by immunoassay, often using diagnostic thresholds derived from the literature. However, commercially available cortisol immunoassays vary in their precision and may cross-react with other steroid hormones; hence, diagnostic thresholds should be assay-specific (8) . Furthermore, only about 5% of circulating cortisol is free and in equilibrium with the cortisol receptor, with approximately 80% bound to corticosteroid-binding globulin (CBG) and the remainder to albumin (9) . Interindividual variability in CBG can result in a difference in the total (measured) cortisol concentration when there is no difference in the free (physiologic) cortisol concentration (10) . Additionally, the capacity of CBG to bind cortisol is saturable at physiological concentrations. Thus, at higher concentrations, a moderate increase in total cortisol may be associated with a large increase in free cortisol (11) .
Liquid chromatography-tandem mass spectrometry (LCMS) provides greater analytical specificity than immunoassays (12) . The costs of LCMS assays are decreasing and they are becoming increasingly available to measure steroid hormones. Furthermore, LCMS has sufficient sensitivity in combination with equilibrium dialysis to measure plasma free cortisol accurately. However, the role of LCMS during ACTH 1-24 stimulation testing in pituitary patients is not known.
Other patient variables are often not considered when interpreting the results of ACTH 1-24 stimulation tests. However, they may be important. For example, sex was reported to influence ACTH 1-24 -stimulated total cortisol secretion in some (13) but not all (14) studies. Furthermore, age, body mass index (BMI), and sex influence adrenal sensitivity to endogenous ACTH pulses (15) . The effect of these variables on ACTH 1-24 -stimulated total and free cortisol secretion is worthy of investigation.
The primary aim of this study was to investigate whether the measurement of total and free plasma cortisol by LCMS during the low-and high-dose ACTH 1-24 stimulation tests better defines HPA status in pituitary patients than total cortisol measured by immunoassay. We also established a reference range for basal and ACTH 1-24 -stimulated plasma total and free cortisol measured by LCMS and assessed the relationship between age, BMI, and sex and ACTH 1-24 -stimulated total and free cortisol concentrations.
Materials and Methods
This open cross-sectional study was undertaken within the Endocrine Research Unit, Repatriation General Hospital, Adelaide, Australia and the Department of Endocrinology, St Vincent's Hospital, Melbourne, Australia. The study was approved by the Southern Adelaide Clinical Human Research Ethics Committee, Adelaide and the Human Research Ethics Committee, St Vincent's Hospital, Melbourne. All subjects provided written informed consent in accordance with the Declaration of Helsinki.
Subjects
We prospectively recruited 60 healthy volunteers aged 20 to 80 years from the general community who had no history of pituitary or adrenal disease and were not taking oral glucocorticoids or estrogens and 21 patients with established pituitary disease. Twelve pituitary patients had had nonfunctioning tumors, 4 acromegaly, 1 Cushing's disease, 1 prolactinoma, 2 congenital hypopituitarism, and 1 hypophysitis. Thirteen pituitary patients were taking glucocorticoid replacement (8 subjects hydrocortisone, 19 Ϯ 6 mg/d; 4 subjects cortisone acetate, 22 Ϯ 3 mg/d; 1 subject prednisolone 5 mg/d), 11 thyroxine, 5 testosterone, 1 oral estrogen, 1 transdermal estrogen, 3 GH, and 4 desmopressin. Fifteen pituitary patients had undergone pituitary surgery and 2 had received pituitary radiotherapy. In all pituitary patients HPA sufficiency (n ϭ 8) or deficiency (n ϭ 13) had been defined by IHT (glucose Ͻ2.2 mmol/L, cortisol cutoff 550 nmol/L) or morning cortisol (deficient Յ100 nmol/L, sufficient Ն500 nmol/L).
Study design
Subjects attended the Endocrine Research Unit, Repatriation General Hospital, or the Department of Endocrinology, St Vincent's Hospital at 9 AM after an overnight fast on 2 occasions about 7 days apart. For subjects taking glucocorticoids, the afternoon glucocorticoid dose was withheld the day before ACTH testing, to ensure testing occurred more than 24 hours after last glucocorticoid administration. On the first visit, height, weight, waist and hip circumference, pulse, and blood pressure were recorded. A cannula was inserted into an antecubital fossa vein for blood sample collections. At each visit, subjects were administered either 1 g ACTH 1-24 (Synacthen; Novartis Pharmaceuticals, Sydney, Australia) IV or 250 g ACTH 1-24 IM, in random order. For the 1 g ACTH 1-24 stimulation test, 250 g ACTH 1-24 was added to 99 mL 0.9% sodium chloride, producing a solution with an ACTH 1-24 concentration of 2.5 g/mL.
Following agitation for at least 2 minutes, 0.4 mL of the diluted ACTH 1-24 solution was drawn up using a 50 U insulin syringe and injected as a bolus directly into the IV cannula, which was then flushed with normal saline. Blood samples were collected at baseline, and 30 and 60 minutes after ACTH administration.
Laboratory analysis
Plasma total cortisol was measured by immunoassay (Elecsys 2010; Roche Diagnostics, Mannheim, Germany; coefficient of variation Ͻ 3%) and by in-house LCMS assay as previously described (16) . In brief, following the addition of an internal standard d4-cortisol and extraction with tert-butylmethyl-ether, plasma total cortisol was measured by LCMS (API 3200 Q Trap; Applied Biosystems, Scoresby, Australia) with selective ion monitoring of mass-to-charge ratio 363-121 for cortisol and 367-121 for d4-cortisol. The coefficient of variation was 3.4% to 6.2% at cortisol concentrations between 70 and 1000 nmol/L. Plasma free cortisol was isolated at 37°C using a commercial equilibrium dialysis kit (Pierce, Rockford, Illinois) and measured by LCMS. Plasma free cortisol was calculated using the following equation: free cortisol ϭ total cortisol dialysate cortisol/retentate cortisol. The Elecsys Cortisol CalSet calibrators were used for both the immunoassay and the LCMS assays. Plasma CBG was measured using a 2-site noncompetitive monoclonal antibody-based ELISA assay, as previously described (17) .
Statistical analysis
Most data were analyzed using SPSS 20.0 for Windows (SPSS Inc, Chicago, Illinois) with 95% confidence intervals (CI) calculated using Analyze-It for Microsoft Excel (version 2.26; Microsoft Corp, Leeds, United Kingdom) and sensitivities and specificities calculated at http://www.vassarstats.net/clin1.html. Results are reported as mean Ϯ SD with P Ͻ .05 considered statistically significant. 2 tests were used to assess categorical variables and unpaired and paired t tests were used to assess independent and dependent continuous variables, respectively. The relationships between age and BMI with CBG and basal and maximal ACTH 1-24 -stimulated (30-minute concentration during 1 g test, 60-minute concentration during 250 g test) total and free cortisol concentrations were assessed by simple linear regression analyses. As the relationships for total cortisol by immunoassay and LCMS were similar, only the LCMS results are reported. If more than one variable (sex, age, BMI) were significantly related to CBG or cortisol in univariate analyses, these were then entered into a multivariate analysis. The sensitivity and specificity of each cortisol assay to predict ACTH deficiency and concordance with previous HPA assessment at each time point were calculated based on the lower limits of the 95% CI derived from normal subjects, with the patients' previous assessment of the HPA axis considered the gold standard.
Results

Subject characteristics (Table 1)
Subjects with pituitary disease had a significantly higher mean waist circumference and waist/hip ratio than controls. In women, mean waist circumference was 13 cm greater in pituitary patients than in normal subjects (P ϭ .001). In men, mean waist circumference was 7 cm greater in pituitary patients, but the difference was not statistically significant (P ϭ .26). The mean BMI of the pituitary patients was 2.7 kg/m 2 higher than controls; however, this difference was not statistically significant. There were no other significant differences in other demographic variables between the 2 groups. In particular, mean CBG concentration was not significantly different in the controls and pituitary patients.
Relationship between sex, age, BMI, CBG, and cortisol in controls
Mean CBG concentration was significantly higher in women than in men (673 Ϯ 135 vs 530 Ϯ 123 nmol/L, P Ͻ .0001). Basal total (464 Ϯ 143 vs 419 Ϯ 93 nmol/L, P ϭ .17) and free (14.6 Ϯ 7.4 vs 16.3 Ϯ 6.1 nmol/L, P ϭ .34) cortisol concentrations were not significantly different in women and men. Thirty minutes after 1 g ACTH 1-24 mean total (814 Ϯ 111 vs 699 Ϯ 108 nmol/L, P Ͻ .0001), but not free (52.3 Ϯ 10.9 vs 53.1 Ϯ 16.3 nmol/L, P ϭ .83), cortisol concentration was significantly higher in women than in men. Sixty minutes after 250 g ACTH 1-24 mean total cortisol concentration was significantly higher (940 Ϯ 122 vs 840 Ϯ 116, P ϭ .002) and mean free cortisol concentration was significantly lower (72.9 Ϯ 12.5 vs 81.3 Ϯ 19.4 nmol/L, P Ͻ .05) in women than in men.
The concentrations of CBG (r ϭ 0.05, P ϭ .74), basal total cortisol (r ϭ 0.19, P ϭ .15), and basal free cortisol (r ϭ 0.21, P ϭ .11) were not significantly correlated with age. Similarly, total cortisol concentrations 30 minutes after 1 g ACTH 1-24 (r ϭ 0.15, P ϭ .26) and 60 minutes after 250 g ACTH 1-24 (r ϭ 0.23, P ϭ .07) were not significantly correlated with age. In contrast, free cortisol concentrations 30 minutes after 1 g ACTH 1-24 (r ϭ 0.38, P ϭ .003) and 60 minutes after 250 g ACTH 1-24 (r ϭ 0.49, P Ͻ .0001; Figure 1 ) were both positively corre- CBG concentration was significantly and negatively correlated with BMI (r ϭ Ϫ0.28, P ϭ .03). However, in a multiple regression analysis CBG concentration was significantly independently related to sex (P Ͻ .0001), but not to BMI (P ϭ .052). Basal and 1 g and 250 g ACTH 1-24 -stimulated total and free cortisol concentration were not significantly correlated with BMI (data not shown).
CI and comparison with previous HPA assessment
The lower limit of the 95% ACTH 1-24 -stimulated CI for the immunoassay were 441 nmol/L 30 minutes after 1 g ACTH , 492 nmol/L 30 minutes after 250 g ACTH , and 606 nmol/L 60 minutes after 250 g ACTH . Mean total cortisol measured by the immunoassay was significantly lower than total cortisol measured by LCMS at each time point ( Table 2 ). The difference in measured cortisol using the 2 methods was, on average, 12% across the range of cortisol concentrations ( Figure 2 ). As such, the lower limits of basal and ACTH 1-24 -stimulated 95% CI for LCMS-measured cortisol were higher than for the immunoassay (Table 2) . (Table 2) .
Plasma cortisol was within the normal range for all 8 pituitary patients with an intact HPA axis at each time point with each assay. As such, the specificity for all assays at each time point was 100%. The 30-minute cortisol concentration during the 1 g ACTH 1-24 stimulation test and the 30-and 60-minute cortisols during the 250 g ACTH 1-24 stimulation tests correctly classified 11 or 12 of the 13 patients with ACTH deficiency with each assay, resulting in a sensitivity of Ն85% (Table 2 ). However, measures of cortisol 60 minutes after 1 g ACTH 1-24 all had a sensitivity below 80%.
Cortisol concentrations were also expressed as a percentage of the lower CI for each assay (Figure 3 ). Two to 4 pituitary patients had ACTH 1-24 -stimulated total cortisol concentrations between 80% and 120% of the lower CI derived from the normal subjects with the immunoassay and LCMS. Excluding one pituitary patient who was considered HPA deficient on a previous IHT but not by either ACTH stimulation test, all pituitary patients with HPA deficiency were correctly classified by measurement of free plasma cortisol with the concentration less than 80% of the lower CI.
Discussion
In this study we measured basal and 1 g IV and 250 g IM ACTH 1-24 -stimulated plasma cortisol by immunoassay and LCMS in normal subjects and patients with pituitary disease. Measurements of total cortisol by immunoassay were, on average, 12% lower than by LCMS, resulting in reference ranges for LCMS-measured total cortisol that were higher than for the immunoassay. In normal subjects, ACTH 1-24 -stimulated total cortisol was significantly higher in women than in men and ACTH 1-24 -stimulated free, but not total, cortisol was positively correlated with age. Using the lower limit of the 95% CI as a diagnostic threshold, total cortisol measured by the immunoassay and LCMS and free cortisol measured by LCMS correctly categorized the HPA status of most patients with pituitary disease, although free cortisol concentrations were better separated from the diagnostic threshold. These findings provide insight into demographic and laboratory factors that affect ACTH 1-24 -stimulated total and free cortisol secretion and the potential role of LCMS-measured free cortisol in pituitary patients.
The benefits of measuring total cortisol by LCMS in patients with pituitary disease have not been fully clarified. In this study we found that ACTH 1-24 -stimulated total cortisol measured by immunoassay correctly categorized most pituitary patients, when an assay-defined reference range from the local population is used. Hence the sensitivities of ACTH 1-24 -stimulated total cortisol by LCMS were comparable to the immunoassay. Although the increased analytical specificity of LCMS may be useful in some cases, we did not demonstrate diagnostic superiority with LCMS. The sensitivity of plasma free cortisol was similar to total cortisol, but free cortisol concentrations showed greater separation from the lower 95% CI of the normal subjects (Figure 3 ). This suggests that plasma free cortisol in pituitary patients may be better separated from the lower limit of cortisol in normal subjects and have clinical utility in patients with total cortisol concentrations around this threshold. The cost effectiveness of measurement of plasma total and free cortisol by LCMS will vary depending on local factors. The capital costs are considerable and, in contrast to immunoassays, measurement of steroid hormones by LCMS requires an extraction step (18) . The combination with equilibrium dialysis entails an additional expense. However, consumable costs are generally less expensive than for immunoassays, which offset other expenses for frequently performed tests.
The pituitary patients in this study were not selected based on their CBG concentration. This may have led to an underestimation of the benefit of measuring plasma free cortisol, as all pituitary patients had a CBG concentration within the 95% CI derived from normal subjects. Measurement of free cortisol is likely to have greater benefit when CBG concentration is abnormal, as ACTH 1-24 -stimulated total cortisol concentration is affected by CBG concentration (19) . In critically ill (20, 21) or chronic liver disease (22, 23) patients with reduced CBG concentrations, plasma or serum free cortisol provides better assessment of the HPA axis than total cortisol. Our patients were assessed when they were stable and well, whereas clinical assessment sometimes occurs when patients are unwell with a low CBG. Conversely oral estrogen increases CBG concentration, but only one pituitary patient was taking oral estrogen. Future studies should explore the role of measuring ACTH 1-24 -stimulated free cortisol in pituitary patients taking oral estrogen.
Our study extends previous findings in several ways. We have established the first reported reference ranges for ACTH -stimulated total and free cortisol measured simultaneously by immunoassay and LCMS. Contrary to what one might intuitively expect for a more specific assay, total cortisol measured by LCMS was, on average, 12% higher than with the Elecsys 2010 immunoassay across the range of cortisol concentrations. We previously demonstrated that measurement of cortisol by immunoassay at room temperature underestimates total plasma cortisol (16, 24) . These studies found that immunoassay-measured cortisol concentrations matched LCMS values once matrix effects are accounted for (16, 24) . A possible explanation for the matrix effect is interference with the immunoassay antibody binding to cortisol due to the high affinity of CBG to cortisol. The LCMS assay is less susceptible to matrix effects than an immunoassay and was referenced to the Elecsys Cortisol CalSet calibrators, which are traceable to IDMS reference materials.
We have also produced the first comparisons of total and free plasma cortisol measured by LCMS during 1 g and 250 g ACTH 1-24 stimulation tests. A potential advantage of the 1 g ACTH 1-24 stimulation test is that it more closely approximates physiologic ACTH concentrations. A disadvantage is that ACTH dilution is required to perform a 1 g stimulation test, which could introduce dosing errors if not rigorously performed. Metaanalyses comparing 1 g and 250 g ACTH 1-24 stimulation tests in pituitary patients using total cortisol measured by immunoassay have produced discordant results, with one reporting greater sensitivity with the 1 g test (25) and another reporting that the 2 tests performed similarly (7) . In our study, where ACTH 1-24 stimulation tests were conducted by a single investigator, the performance of the 1 g and 250 g ACTH 1-24 stimulation tests was similar for both the immunoassay and the LCMS, when appropriate reference ranges were used.
The time after ACTH 1-24 administration of cortisol is measured lacks consistency in the literature, particularly during the 250 g test (25) . Some authors have concluded that the 30-minute time point is superior to 60 minutes as cortisol concentration at the 30-minute time point better reflects peak cortisol during an IHT (26) . In our study following IV administration of 1 g ACTH 1-24 , the cortisol peak occurs at 30 minutes in 57 of 60 (95%) normal and 20 of 21 (95%) pituitary subjects and the 60-minute time point lacked sensitivity to determine HPA status. In contrast, following 250 g ACTH 1-24 administered IM, the cortisol peak was at 60 minutes in all normal and 19 of 21 (90%) pituitary subjects. In the 250 g ACTH test, measurements of cortisol at 30 and 60 minutes performed similarly when time-appropriate diagnostic thresholds were used.
This study also provides insight into the relationship between patient factors and ACTH 1-24 -stimulated cortisol secretion. Consistent with some (13), but not all (14) , studies, we found that peak total cortisol was higher in women than in men after ACTH stimulation. This finding was due to sex differences in CBG concentration. In contrast, maximal free cortisol concentration was lower in women after 250 g, but not 1 g, ACTH . Our results suggest that optimal interpretation of ACTH stimulation tests using both total and free cortisol should be based on sex-specific reference ranges.
Consistent with previous studies (13, 14, 27) , we did not find a significant relationship between age and ACTH 1-24 -stimulated total cortisol concentrations. However, we do report a positive correlation between age and maximal ACTH 1-24 -stimulated free cortisol. This finding was not explained by a change in CBG concentration, which was not significantly associated with age. Our data suggest that age-specific reference ranges may improve interpretation of ACTH 1-24 -stimulated free cortisol concentrations. Plasma free cortisol concentration following ACTH stimulation is dependent on cortisol secretion, the volume of distribution for free cortisol and free cortisol clearance. Our study does not provide insight into which of these factors are affected by age. However, the finding is of interest, because if free cortisol concentration following ACTH stimulation increases with age, it may contribute to the age-related increase in total and visceral fat mass and reduction in lean body mass and bone mineral density, which parallel changes found in glucocorticoid excess (28 -30) . This could be a topic of further study.
We acknowledge our study is subject to limitations. Most importantly, the number of pituitary patients is modest and limited our ability to compare assays, particularly as the cortisol immunoassay correctly classified most patients. However, our data suggest that at most 5% of pituitary patients may be correctly classified by free cortisol and not total cortisol. Another limitation is that pituitary patients were categorized as HPA sufficient or deficient based on previous (often 3-6 weeks postoperatively) assessment and HPA status can change over time. In particular, one pituitary patient appeared HPA sufficient on basal, 1 g, and 250 g ACTH 1-24 -stimulated cortisol concentrations despite unequivocally failing to achieve an adequate cortisol peak during an IHT 5 weeks after transsphenoidal surgery (glucose nadir 1.2 mmol/L, cortisol peak 436 nmol/L). HPA function can recover some months following pituitary surgery (31) . This is the likely scenario because this patient has subsequently stopped hydrocortisone with no adverse effects. Finally, the diagnostic thresholds following ACTH 1-24 stimulation were generated from 60 healthy volunteers, a sample size that was insufficient to generate sex-and age-specific reference ranges. Nevertheless, the sample size is not dissimilar to other studies of ACTH 1-24 stimulation in normal subjects, who have defined reference ranges for cortisol immunoassays from 30 to 100 subjects (13, 14, 27, 32) .
In summary, sex and age are important variables to consider when assessing ACTH 1-24 -stimulated total and free cortisol, respectively. Measurements of cortisol by the Elecsys 2010 immunoassay are 12% lower than those attained using LCMS, supporting the need for assay-specific reference ranges. Although the sensitivities of total and free plasma cortisol after ACTH 1-24 stimulation are generally similar, free plasma cortisol may provide greater separation from the diagnostic threshold. Future studies should examine the role of LCMS-measured free plasma cortisol after ACTH 1-24 stimulation in a larger cohort of pituitary patients close to the diagnostic threshold and in patients taking oral estrogen.
